Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma

Modern Pathology

Volumn 28, Issue 10, 2015, Pages 1383-1389

  Riazy, Maziar ^a,b   Kalloger, Steve E ^b,c   Sheffield, Brandon S ^a,b   Peixoto, Renata D ^d   Li Chang, Hector H ^a,b   Scudamore, Charles H ^a,b,c   Renouf, Daniel J ^b,c,d   Schaeffer, David F ^a,b,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Pancreas Centre BC   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PYRIMIDINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; STAINING; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR CELL; CARCINOMA, PANCREATIC DUCTAL; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS;

EID: 84942982176     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.89     Document Type: Article

References (25)

1. Sener SF, Fremgen A, Menck HR et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189: 1-7.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Simard EP, Ward EM, Siegel R et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-128.
4. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-172.
5. Wagner M, Redaelli C, Lietz M et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-594.
6. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
7. Oettle H, Neuhaus P, Hochhaus A et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310: 1473-1481.
8. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304: 1073-1081.
9. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806.
10. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-1113.
11. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006;7:335-346.
12. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-421.
13. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013;339: 1546-1558.
14. Kato M, Takano M, Miyamoto M et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol 26:40-452014.
15. Sinicrope FA, Sargent DJ. Molecular pathways: micro-satellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506-1512.
16. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6.
17. Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19-33.
18. Nakata B, Wang YQ, Yashiro M et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 2002;8:2536-2540.
19. Ottenhof NA, Morsink FH, Ten Kate F et al. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr) 2012;35:119-126.
20. Yamamoto H, Itoh F, Nakamura H et al. Genetic and clinical features of human pancreatic ductal adenocar-cinomas with widespread microsatellite instability. Cancer Res 2001;61:3139-3144.
21. Dong X, Li Y, Hess KR et al. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist 2011;16:61-70.
22. Maple JT, Smyrk TC, Boardman LA et al. Defective DNA mismatch repair in long-term (4 or =3 years) survivors with pancreatic cancer. Pancreatology 2005;5:220-227; discussion 7-8.
23. Laghi L, Beghelli S, Spinelli A et al. Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One 2012;7:e46002.
24. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohisto-chemistry. J Mol Diagn 2008;10:293-300.
25. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-277.